Abstract Over the last decade, extensive progress has been made with regard to our understanding of the molecules that regulate skeletal muscle regeneration. Satellite cells are musclespecific stem cells located under the basal lamina of muscle fibers, which are responsible for muscle regeneration. This precise coordination of complex stem cell responses throughout adult life is regulated by evolutionarily conserved signaling networks that cooperatively direct and control. This process includes the activation, proliferation, and differentiation of stem cells. This highly regulated process of tissue regeneration recapitulates embryonic organogenesis with respect to the involvement of interactive signal transduction networks. Indeed, various modulators such as insulin-like growth factor-I (IGF-I), hepatocyte growth factor (HGF), and leukemia inhibitory factor (LIF) have been shown to stimulate the activation and proliferation of satellite cells. PI3K (phosphatidylinositol 3-kinase)/Akt/mTOR (mammalian target of rapamycin), calcineurin, and serum response factor (SRF) seem to contribute to muscle regeneration by regulating differentiation of satellite cells. In contrast, myostatin inhibits these processes through forkhead box O (FOXO) and/or SMAD 2/3-dependent signaling. In this review, the recent findings for muscle regeneration are described.
Introduction
Skeletal muscle contractions power human body movement, and are essential for maintaining stability. Skeletal muscle tissue accounts for almost half of the human body mass and, in addition to its power-generating role, is a crucial factor in maintaining homeostasis. Given its central role in human mobility and metabolic function, any deterioration in the contractile, material, and metabolic properties of skeletal muscle has an extremely important effect on human health.
Upon tissue injury, the cues released by the inflammatory component of the regenerative environment instruct somatic stem cells to repair the damaged area 1) . An elucidation of the molecular events underpinning the interplay between the inflammatory infiltrate and tissue progenitors is crucial to devising new strategies for implementing regeneration of diseased or injured tissues. Regeneration of diseased muscles relies on muscle stem cells (satellite cells) located under the basal lamina of muscle fibers 2) , which are activated in response to cytokines and growth factors 3) . The current lack of knowledge, on how external cues coordinate gene expression in these cells, precludes their selective manipulation through pharmacological interventions.
The inflammatory infiltrate is a transient, yet essential, component of the satellite cell niche, and provides the source of locally-released cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor-α (TNF-α), which regulate muscle regeneration 4) . As an inducible element of the satellite cell niche, the inflammatory infiltrate provides an ideal target for selective interventions aimed at *Correspondence: ksakuma@las.tut.ac.jp Abbreviations: ActRIIB, activin receptor IIB; ALK, activin receptor-like kinase; CCL, chemokine (C-C motif) ligand; eIF, elongation initiation factor; FAK, focal adhesion kinase; FOXO, forkhead box O; GSK-3β, glycogen synthase 3-β; HDAC, histone deacetylase; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; IL, interleukin; LIF, leukemia inhibitory factor; MAPK, mitogen-activated protein kinase; MEF2, myocyte enhancer factor 2; MRTF, myocardinrelated transcrition factor; mTOR, mammalian target of rapamycin; mTORC, mTOR signaling complex; MuRF, muscle ring finger; NFAT, nuclear factor of activated T cells; NF-κB, nuclear factor-kappa B; NO, nitric oxide; NOS, nitric oxide synthase; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; STARS, striated muscle activators of Rho signaling; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; TSC, tuberous sclerosis complex; uPA, urokinase-type plasminogen activator; 4E-BP, 4E binding protein manipulating muscle regeneration 5) . However, because local inflammation regulates multiple events within the regeneration process, global anti-inflammatory interventions have both positive and negative effects on satellite cells 6) . Thus, it is important to elucidate the intracellular signaling by which inflammatory cytokines deliver information to individual genes in satellite cells.
Similar to the embryonic stem cells that build organs, adult stem cells, that regenerate organs, are capable of symmetric and asymmetric division, self-renewal, and differentiation. Several extrinsic factors, including hepatocyte growth factors (HGFs) 7) , nitric oxide (NO) 8) , wingless-type family members (Wnt) 9) , fibroblast growth factors (FGFs) 10) , insulin-like growth factors (IGFs) 11) , and transforming growth factor-β (TGF-β) families of signaling molecules, are known to affect these processes. Many of the signals which modulate satellite cells are an incessant part of their environment; thus, numerous modes of regulation must exist for a satellite cell to fine tune and modulate its response to extrinsic cues 12) . This review aims to outline the molecular and cellular mechanisms of muscle regeneration.
Early immune response
Two distinct macrophage populations exist. Classically activated (Th1 or type I) macrophages are induced by interferon-γ, alone or in concert with microbial stimuli (e.g. lipopolysaccharide) or selected cytokines (e.g. TNF-α). They have pro-inflammatory functions: classically activated macrophages produce effector molecules (reactive oxygen and nitrogen intermediates) and inflammatory cytokines (IL-1β, TNF-α, IL-6). Type I macrophages characteristically and selectively express proinflammatory chemokines, in particular CCL [chemokine (C-C motif) ligand] 3. Alternatively activated (Th2 or type II) macrophages comprise cells exposed to IL-4 or IL-13, immune complexes, IL-10, and glucocorticoid; they participate in polarized Th2 reactions, promote killing and encapsulation of parasites. Moreover, alternatively activated macrophages are involved in wound healing and have immunoregulatory functions 13) . Studies in rats have shown that type I macrophages are associated with muscle necrosis, whereas type II macrophages are associated with regenerative myofibers 14) . Of striking interest, these cells, once within the muscle, apparently acquire a type II phenotype, revealing a previously ignored plasticity. Recognition and phagocytosis of muscle cell debris is probably a critical event. Indeed while type I macrophages enhance the proliferation of local myogenic precursor cells, type II macrophages stimulate their fusion and differentiation 15) . Some molecular interactions are required for macrophage recruitment and function in damaged muscles. The muscle tissue of CCR2 null mutant mice (C-C chemokine receptor 2 knockout mice) undergoes regenerating defects including fibrosis and calcification after muscle damage. In addition, uPA (urokinase-type plasminogen activator)-/-macrophages fail to infiltrate damaged muscle 16) . This failure is associated with defective muscle regeneration, demonstrating that uPA is required for the homeostatic response to injury. Expression of uPA is apparently required for the expression of IGF-I, a central regulator of muscle regeneration 17) . IGF-I suppresses the expression and activity of macrophage migration inhibitory factor and the transcription factor NF-κB, possibly directly regulating the persistence of inflammatory responses 18, 19) .
Hepatocyte growth factor and neuronal nitric oxide synthase
By 24 hours after muscle injury, satellite cells enter the G1/S phase of the cell cycle 20) . Two factors have been demonstrated to activate quiescent satellite cells. The first is HGF. HGF is the only growth factor that has been established to have the ability to stimulate quiescent satellite cells to enter the cell cycle early in a culture assay and in vivo 21, 22) . HGF is localized in the extracellular domain of un-injured skeletal muscle fibers, through a possible association with glycosaminoglycan chains of proteoglycans that are essential components of the extracellular matrix, and following injury, quickly associates with satellite cells 23 ) by binding to cell surface c-Met receptors 22) . The second component shown to be involved in satellite cell activation is NO, possibly through activation of matrix metalloproteinases, which induces the release of HGF from the extracellular matrix 23) . Studies in vitro and in vivo, using rodent muscle, have shown HGF and NO to regulate the activity of many satellite cells [22] [23] [24] . Intriguingly, inhibition of NO production inhibits HGF release, c-Met/HGF co-localization, and satellite cell activation 23) . NO is a short-lived free radical that is well known as a freely diffusible and ubiquitous molecule produced by nitric oxide synthase (NOS) from the L-arginine of substrates. The NO radical is normally produced in very low level pulses by muscles under conditions where satellite cells are quiescent 25) , and the expression and activity of constitutive NOS (nNOS and eNOS) is up-regulated by exercise, loading injury, shear force, and mechanical stretch.
Proliferation process of satellite cells
Leukemia inhibitory factor. Leukemia inhibitory factor (LIF) is a newly discovered myokine 26) . Today, LIF is known to have a wide array of functions, including acting as a stimulus for platelet formation, the proliferation of hematopoietic cells, bone formation, neural survival and formation, muscle satellite cell proliferation and acute phase production by hepatocytes 27) . Several tissues, including skeletal muscle, express LIF. LIF is implicated in conditions affecting skeletal muscle growth and regenera-inhibited the action of IGF-I. Taken together, these results demonstrate a novel, central and exclusive involvement of PKCδ in mediating the action of IGF-I in human skeletal muscle cells, with an additional PKCδ-dependent contribution of the MAPK pathway in C2C12 myoblasts.
Differentiation of satellite cells

Calcineurin. Changes in intracellular Ca
2+ concentrations regulate the physiological activities of calmodulin. Calmodulin is a multifunctional signal transducer that undergoes conformational changes before activating a wide range of binding substrates, mainly downstream phosphatases (calcineurin) and kinases (CaMKs) 45) . The serine/threonine phosphatase calcineurin plays a major role in a wide variety of physiological and pathological processes, including the immune response, neuronal plasticity, and cardiac development and hypertrophy 46) . In skeletal muscle, calcineurin is required in a number of key developmental processes, namely enhanced muscle cell differentiation, and in a fiber type context, conversion to a slow (oxidative) muscle phenotype 47, 48) . Calcineurin's enzymatic activity requires a catalytic (CnA, 59 to 62 kDa) and a calcium-binding regulatory (CnB, 19 kDa) subunit, comprising several isoforms coded by different genes or generated by alternative splicing. The CnA subunit includes protein domains conferring catalytic activity, CnB interaction, and calmodulin-binding and a C-terminal autoinhibitory domain, which blocks the catalytic site if removed in response to an increase in calcium. Three CnA genes have been described: CnAα and CnAβ are ubiquitously expressed, whereas CnAγ is restricted to brain and testis. Two CnAβ isoforms, CnAβ1 and CnAβ2, which differ in their C-terminal domain, are encoded by alternatively spliced transcripts 49) . The typical autoinhibitory domain present in CnAβ2 and other calcineurin isoforms is absent from CnAβ1, in which an unrelated C-terminal domain is generated by the translation of intronic sequences 50) . This novel domain is preserved in the CnAβ1 orthologues from different species 50) , especially in higher vertebrates, suggesting an evolutionarily conserved role for this calcineurin variant. When activated by Ca 2+ /calmodulin binding, calcineurin affects gene expression by dephosphorylating specific substrates, including the four calcineurin-dependent members of the nuclear factor of activated T cells (NFAT) gene family, NFATc1, NFATc2, NFATc3 and NFATc4. Following dephosphorylation, NFAT translocates from the cytoplasm to the nucleus and activates target genes in cooperation with other transcription factors 51) . Calcineurin activity and the ability to activate NFAT are directly antagonized by the immunosuppressive cyclophilins and FK506 binding proteins (FKBPs), respectively 52, 53) , or by endogenous protein inhibitors, such as Cain (also known as calcineurin inhibitory protein or cabin-1) and myocyte-enriched calcineurin-interacting protein (MCIP) 1, the latter betion [28] [29] [30] . Indeed, LIF knockout mice showed a decrease in the area occupied by regenerating myofibers after crush injury compared to wild-type mice, which was restored by administration of exogenous LIF 31) . Administration of LIF to the site of crush injury in wild-type mice increased the area occupied by regenerating fibers with an associated increase in average myofiber diameter 31, 32) . These original studies suggested that enhanced regeneration and increases in fiber size occurred, at least, in part, via stimulation of the proliferation of muscle-forming myoblast cells, thus providing more cells to fuse to and increase the size of regenerating fibers.
Early descriptions of LIF, as a possible mitogen for myoblasts, suggested that LIF treatment increased the number of human and mouse-derived primary myoblast cells in a dose-dependent manner after several days of culture, with the earliest increases noticeable after 6 days 33,34) . Hunt et al. 35) found that LIF treatment significantly reduced staurosporine-induced apoptotic DNA fragmentation by 37% and also reduced the proteolytic activation of caspase-3 by 40% compared to controls. This apoptosis-inhibiting role of LIF was completely abolished by a PI3K (phosphatidylinositol 3-kinase) inhibitor (wortmannin). Therefore, LIF appears to increase the number of satellite cells by promoting proliferation and blocking apoptosis.
Insulin-like growth factor-I and MAPK (proliferation phase)
. IGF-I is a critical factor involved in skeletal muscle hypertrophy in vivo as well as in cultured myotube enlargement in vitro [36] [37] [38] . IGF-I is thought to induce muscle growth through the increased proliferation of satellite cells and the enhancement of protein translation resulting in an increase in the rate of protein synthesis 36, 39) . In addition to stimulating myoblast proliferation, IGF-I stimulates myoblast differentiation 40) . For example, IGF-I inhibits production of myogenin, a protein that stimulates muscle cell differentiation, thus allowing increased myoblast proliferation. However, the interplay between the elements of these intracellular signaling pathways has been described based on results of experiments with skeletal muscle cell types of different species and under various conditions. Namely, in mouse and rat skeletal muscle preparations, the involvement of both the MAPK (mitogen-activated protein kinase) pathway and MAPKindependent signaling mechanisms, including PI3K/Akt and protein kinase C (PKC), was equally documented [41] [42] [43] . In primary cultured human skeletal muscle cells, Czifra et al. 44) demonstrated that the proliferation-enhancing effect of IGF-I was completely inhibited by the PKCδ-specific inhibitor, rottlerin, but not by inhibitors of the "conventional" PKCα and γ isoforms or by inhibitors of the MAPK or PI3K pathway. In addition, overexpression of a kinase inactive mutant of PKCδ prevented the proliferating action of IGF-I. Furthermore, they showed in mouse C2C12 cells that the MAPK inhibitor PD098059 partially calcineurin directly binds and dephosphorylates (inactivates) Akt; FOXO indirectly activates Akt by inhibiting calcineurin phosphatase activity 68) . In murine C2C12 myotubes, Akt was shown to antagonize calcineurin signaling by causing hyperphosphorylation of NFATc1 51) . Interaction between CnAβ1 and FOXO during muscle regeneration is a very feasible idea, although it has not been demonstrated in adult skeletal muscle in vivo.
Serum response factor. Serum response factor (SRF) is an ubiquitously expressed member of the MADS box transcription factor family, sharing a highly conserved DNA-binding/dimerization domain, which binds the core sequence of SRE/CArG boxes [CC(A/T)6GG] as homodimers 69) . Functional CArG boxes have been found in the cis-regulatory regions of various muscle-specific genes, such as the skeletal α-actin 70) , muscle creatine kinase, dystrophin, tropomyosin, and myosin light chain 1/3 genes. The majority of SRF targets are genes involved in cell growth, migration, cytoskeletal organization, and myogenesis 71, 72) . It is proposed that the transcriptional activity of SRF is regulated by MuRF-2 73) and striated muscle activator of Rho signaling (STARS) 74) . At the M-band, the mechanically modulated kinase domain of titin interacts with a complex of the protein products of the atrogenes NBR1, p62/SQSTM1 and MuRF 73, 75) . This complex dissociates under mechanical arrest, and MuRF-1 and MuRF-2 translocate to the cytoplasm and the nucleus 73, 76) . One of the probable nuclear targets of MuRFs is SRF 73) , suggesting that the MuRF-induced nuclear export and transcriptional repression of SRF may contribute to amplifying the transcriptional atrophy program 77) . Thus, it is possible that the synergistic transactivation of SRF and SRF-linked molecules is abrogated by MuRF-2 in vivo. On the other hand, SRF activity is exquisitely sensitive to the state of actin polymerization. G-actin monomers inhibit SRF activity, whereas polymerization of actin occurs in response to serum stimulation and RhoA signaling. In this pathway, signal inputs lower the ration of globular actin (G-actin) to fibrillar actin (F-actin) thereby liberating the binding of myocardin-related transcription factor (MRTF)-A to G-actin resulting in the nuclear accumulation of MRTF-A and subsequent SRF-dependent gene expression 78) . It has been well established that overexpression of STARS contributes to the nuclear translocation of MRTF-A and MRTF-B 74, 79) , and these factors activate SRF translocation.
SRF was first shown to be essential for both skeletal muscle cell growth and differentiation in experiments performed with C2C12 myogenic cells. In this model, SRF inactivation abolished MyoD and myogenin expression, preventing cell fusion in differentiated myotubes 80) . SRF also enhances the hypertrophic process in muscle fibers 81, 82) . For example, the authors showed that, in mechanically overloaded rat muscles, SRF protein is coing particularly abundant in slow-twitch muscle, but not detectable in fast-twitch glycolytic muscles 54, 55) . More recently, reporter assays using cultured myoblasts indicated that the transcriptional activation of NFAT by calcineurin was also inhibited by calsarcin-2 56) . IGF-I positively regulated not only the proliferation, but also the differentiation of satellite cells/myoblasts in vitro possibly through a calcineurin-dependent pathway. Since activated calcineurin promotes the transcription and activation of myocyte enhancer factor 2 (MEF2), myogenin, and MyoD [57] [58] [59] , calcineurin seems to control satellite cell differentiation and myofiber growth and maturation, all of which are involved in muscle regeneration 60, 61) . In fact, the authors' previous study 60) showed a marked increase in the amount of calcineurin protein and the clear colocalization of calcineurin and MyoD or myogenin in many myoblasts and myotubes during muscle regeneration. In addition, it was shown that the inhibition of calcineurin by CsA induced extensive inflammation, marked fiber atrophy, and the appearance of immature myotubes in regenerating muscle compared with placebo-treated mice 60) . Several other studies indicated such defects in skeletal muscle regeneration when calcineurin was inhibited 62, 63) , whereas transgenic activation of calcineurin is known to markedly promote the remodeling of muscle fibers after damage 50, 64) . Many researchers have utilized CsA, in different amounts, to determine the downstream modulators of calcineurin signaling. The authors found that intraperitoneal CsA daily treatment (25 mg/Kg/day) enhanced the expression of myostatin and Smad3 mRNA in regenerationdefective tibialis anterior muscle after an injection of bupivacaine 61) . The possibility that myostatin is a downstream mediator of calcineurin signaling has been indicated by experiments with two different types of transgenic mice 65) . In addition, calcineurin's pharmacological inhibition caused a decline in the transcription and activation of myogenin and MyoD, during myogenic differentiation, by a downregulation of MyoD expression 66) . Considering these findings, calcineurin seems to block the myostatin/ SMAD3 pathway to enhance the expression of myogenic differentiation factor (MyoD) during muscle regeneration in vivo. Using CsA treatment in vivo, recent evidence, including that obtained by the authors, has also identified Id1 59, 61) , Id3 59) , and Egr-1 59) as possible downstream negative hypertrophic effector targets of the calcineurin/NFAT signaling pathway.
FOXO-induced expression of Atrogin-1 has been shown to inhibit calcineurin activity 67) . More recently, the calcineurin variant CnAβ1 was suggested to block the nuclear localization of the FOXO protein and the expression of several genes targeted by FOXO [the muscle ring finger (MuRF) 1, GADD45A, PMAIP1, and atrogin genes] in C2C12 myoblasts 50) . In addition, transgenic upregulation of CnAβ1 expression promotes the remodeling of cardiotoxin-treated muscle fibers 50) . In cardiomyocytes, localized with MyoD and myogenin in myoblast-like cells during the active differentiation phase 82) . Interestingly, HAS-Cre:Sf/Sf mice exhibited defects in the regeneration of skeletal muscle after the injection of cardiotoxin, although the exact mechanism involved has not been elucidated. The SRF-depleted mice showed decreased levels of IGF-I and IL-4 mRNA at 2 months of age. Since mice with a downregulated IL-4 pathway regenerated normally 83) , Charvet et al. 84) proposed that the regenerative defect was attributable to the decreased expression of IGF-I. During muscle regeneration, the defect of IGF-I expression may affect downstream molecules such as calcineurin 85) and Akt 86) , although Charvet et al. 84) did not investigate whether HAS-Cre:Sf/Sf mice had defective calcineurin-and/or Akt-signaling in the skeletal muscles. However, several downstream candidates of these signaling molecules, the NFATc2 87) , MyoD 58) , myogenin 59) , and myostatin 61, 65) , were modulated by the SRF mutation 84) . Therefore, the impaired calcineurin-and/or Aktdependent signaling elicited by the reduction in IGF-I may regulate the regenerative defect recognized in HASCre:Sf/Sf mouse muscles.
PI3K/Akt/mTOR pathway.
A central pathway involved in hypertrophy is regulated at the translational level by the serine/threonine kinase Akt. In muscle, Akt is activated by upstream PI3K, induced either by receptor binding or by integrin-mediated activation of focal adhesion kinase (FAK), such as in cardiac myocytes 88, 89) . The striking effect of Akt1 on muscle size was demonstrated by the transient transfection of a constitutively active inducible Akt1 transgene in skeletal muscle in vivo 90) . In addition, muscle mass was completely preserved in denervated transgenic Akt mice 91) . Akt activation causes multiple changes in muscle gene expression, documented by microarray analysis 92) . Possible downstream regulators of Akt, mammalian target of rapamycin (mTOR) and glycogen synthase 3-β (GSK-3β) play a crucial role in the regulation of translation 93) . More recently, it has been shown that mTOR exists in two functionally distinct multi-protein signaling complexes, mTOR signaling complex (mTORC)1 and mTORC2 94) . Akt activates mTOR via phosphorylation and inactivation of tuberous sclerosis complex-2 95) . In general, only signaling by mTORC1 is inhibited by rapamycin; and thus the growth regulatory effects of rapamycin are believed to be primarily exerted through the mTORC1 complex 96) . It is now widely accepted that signaling by mTORC1 is involved in the regulation of several anabolic processes including protein synthesis, and ribosome biogenesis, as well as catabolic processes such as autophagy 96) . In skeletal muscle, signaling by mTORC1 has been shown to be regulated by a variety of different stimuli that control skeletal muscle mass. For example, signaling by mTORC1 is activated in response to hypertrophic stimuli such as increased mechanical loading, feeding and growth factors 97, 98) . In addition, overexpression of constitutively active Akt activates mTORC1 signaling and induces hypertrophy through a rapamycin-sensitive mechanism 99) . Since signaling through PI3K/Akt can regulate mTORindependent growth regulatory molecules such as GSK-3β, tuberous sclerosis complex 2 (TSC2), and FOXO transcription factors 100) , it was not clear if signaling by mTORC1 was sufficient, or simply permissive, for the induction of hypertrophy. For example, Hornberger et al. 101) found that stretch-induced activation of mTOR signaling was not abolished in the skeletal muscle of Akt1-/-mice. Furthermore, Akt-independent stimulation of mTOR may be positively or negatively regulated by phosphorylation of TSC2. For instance, TSC2 is inhibited by FAK in 293T cells 102) suggesting that up-regulation of FAK expression with increased loading could stimulate protein synthesis via TSC2 inhibition. All these regulatory influences may explain the rise in the level of phosphorylated 70 kDa ribosomal protein S6 kinase (p70S6K) 103) . Therefore, mTOR is currently thought to be the major hub for the integration of an array of upstream signaling pathways which, when activated, ultimately result in increased translational efficiency 104, 105) . Two of the most studied mTORC1 targets are the eukaryotic initiation factor 4E binding protein 1 (4E-BP1) and p70S6K, which both play important roles in the initiation of mRNA translation. mTOR phosphorylates and activates p70S6K, which results in increased translation either directly or indirectly by activating initiation and elongation, elongation initiation factor 2 (eIF2), eIF4E (through 4E-BP) and eEF2 104) . In addition, Akt also phosphorylates and inactivates GSK-3β, thereby activating translation via the initiation factor eIF2B 106) . Other functions of Akt include the negative regulation of protein degradation by inhibiting FOXO-mediated proteasome activity 107) . Growth and maturation of the muscle cells is achieved through a second-stage fusion, which occurs between the nascent myofibers/myotubes and myoblasts. Although many regulators of this fusion process have been revealed in recent years 108) , a better understanding of the regulation is still needed. mTOR is one of the candidates regulating the fusion. mTOR signaling regulates a wide range of biological processes, including cell growth, various types of cellular differentiation, and metabolism 109, 110) . mTOR assembles two biochemically and functionally distinct protein complexes, mTORC1 and mTORC2, which are sensitive and insensitive to rapamycin, respectively 109) . Rapamycin-sensitive mTORC1 signaling has emerged as a key regulator of skeletal muscle differentiation and remodeling. Rapamycin inhibits myoblast differentiation in vitro 111, 112) , compensatory myofiber hypertrophy in vivo, and regrowth of myofibers after atrophy 99) . The regulation of skeletal myocyte differentiation by mTORC1 occurs at two stages via distinct mechanisms. mTORC1 controls the initiation of myoblast differentiation by regulating IGF-II expression 112) , whereas late-stage myocyte fusion, leading to myotube maturation, is regulated by mTORC1 through a yet to be identified factor 113) . More recent findings pointed out that the fusion factor targeting mTORC1 is follistatin, during the late differentiation phase. Sun et al. 114) have found that, in C2C12 cells differentiating for 24 to 72 h, miR-1 luciferase (enhancer) activity was markedly downregulated after treatment with rapamycin, but not after treatment with wortmannin (PI3K inhibitor) or SB203580 (MAPK inhibitor). In addition, rapamycin increased the amount of histone deacetylase 4 (HDAC4) protein and reduced follistatin mRNA and MyoD protein levels in C2C12 and C3H10T1/2 cells. Furthermore, daily administration of TSA and a single dose of adenovirusexpressing follistatin rescued the defective muscle regeneration caused by treatment with rapamycin. Sun et al. 114) proposed the intriguing hypothesis that mTORmiR-1 promotes myocyte fusion by recruiting HDAC4-follistatin during myoblast differentiation in vitro and skeletal muscle regeneration in vivo. Fig. 1 summarizes the calcineurin-, SRF-, and Akt-dependent signaling in muscle regeneration.
Myostatin -the other modulator of muscle regeneration
Myostatin was first discovered during screening for novel members of the TGF-β superfamily, and shown to be a potent negative regulator of muscle growth 115) . Like other TGF-β family members, myostatin is synthesized as a precursor protein that is cleaved by furin proteases to generate the active C-terminal dimer. When produced in Chinese hamster ovary cells, the C-terminal dimer remains bound to the N-terminal propeptide (NTPP), which remains in a latent, inactive state 116) . Most, if not all, of the myostatin protein that circulates in blood, also appears to exist in an inactive complex with a variety of proteins, including propeptides 117) . The latent form of myostatin seems to be activated in vitro by dissociating the complex with either acid or heat treatment 116, 117) or by proteplytic cleavage of a propeptide /CaM complex to the calcinuerin regulatory subunit leads to its activation. Activated calcineurin dephosphorylates a range of transcription factors (including MEF2 and NFAT), and promotes myogenic differentiation. Myosin-actin interaction, by mechanical loading, activates STARS/MRTF-A/SRF signaling 74) . Charvet et al. 84) proposed that SRF-dependent signaling regulates muscle regeneration by promoting myogenic differentiation, probably due to the induction of IGF-I and IL-4 expression. IGF-I produced by the regenerating muscle activates PI3K/Akt/mTOR signaling resulting in a positive protein balance. One part of mTOR (mTORC1) enhances myotube differentiation at later stages probably through the induction of follistatin expression. CaM: calmodulin, IRS-1: insulin receptor substrate-1 with members of the bone morphogenic protein 1/Tolloid (BMP-1 /TLD) family of metalloproteases 116) . Mutations in myostatin can lead to massive hypertrophy and/or hyperplasia in developing animals, as evidenced by knockout experiments in mice. Moreover, mouse skeletal muscle, engineered to overexpress the myostatin propeptide, the naturally occurring myostatin inhibitor follistatin, or a dominant-negative form of ActRIIB (the main myostatin receptor 115) ), displays, in each case, similar, if not greater, increases in size 115) . Myostatin binds to and signals through a combination of Activin IIA/B receptors on the cell membrane, but has higher affinity for ActRIIB. On binding to ActRIIB, myostatin forms a complex with a second surface type I receptor, either activin receptor-like kinase (ALK4 or ActRIB) or ALK5 to stimulate the phosphorylation of receptor SMAD and the SMAD2/3 transcription factors in the cytoplasm. This leads to the assembly of SMAD2/3 with SMAD4 to form a heterodimer that is able to translocate to the nucleus and activate the transcription of target genes 118) . Myostatin levels increase with muscle atrophy due to unloading in mice and humans 29, [119] [120] [121] , and with severe muscle wasting in HIV patients 122) . For example, the authors, using healthy university students, showed significantly increased levels of myostatin mRNA in muscle tissue after the unilateral suspension of a hindlimb for two weeks. In addition, administration of myostatin in vivo to adult mice induceed profound muscle loss analogous to that seen in human cachexia syndrome 117) . Together these studies suggest that increased levels of myostatin lead to muscle wasting.
Studies indicate that myostatin inhibits the activation, differentiation, and self-renewal of satellite cells [123] [124] [125] , and expression of the muscle regulatory factors crucial for the regeneration and differentiation of myofibers 123, 126) . Intriguingly, loss of SMAD3, a possible mediator for myostatin, also led to defective satellite cell functionality. Indeed, Ge et al. 127) observed decreased satellite cell numbers in skeletal muscle from SMAD3-null mice, probably due to the reduced propensity for self-renewal. Furthermore, in vitro analysis of primary myoblast cultures identified that SMAD3-null myoblasts exhibit impaired proliferation, differentiation, and fusion. A more recent study 128) clearly indicated that the mice with null mutation of SMAD3, an intracellular mediator for both myostatin and TGF-β, exhibited incomplete recovery of muscle weight and myofiber size after muscle injury. Morphological analysis suggested impaired inflammatory response and a reduced number of activated myoblasts during the early stage of muscle regeneration in SMAD3-null mice. In addition, SMAD3-null regenerated muscle had decreased oxidative enzyme activity and impaired mitochondrial biogenesis possibly due to the downregulation of gene encoding TFAM, a master regulator of mitochondrial biogenesis.
One of the known downstream targets of SMAD signaling is MyoD. Interestingly, myostatin downregulates MyoD expression in an NF-κB-independent manner 129) . Myostatin also inhibits Pax3 expression, which is possibly an upstream target of MyoD 129) . Recently, it was found that FOXO1 and SMAD synergistically increase the expression of myostatin mRNA and its promoter activity in C2C12 myotubes 66) . Taken together, myostatinmediated signaling activates FOXO, and this leads to the expression of ubiquitin ligases.
Conclusions
Skeletal muscles in young mammals possess a robust capacity for self repair, whereas impaired muscle regeneration occurs in sarcopenic animals due, in part, to defective Notch-dependent signaling [130] [131] [132] . Although both PI3K/Akt/mTOR-and SRF-dependent signals are potent regulators for muscle hypertrophy, these factors seem to also have a crucial role in muscle regeneration, probably due to enhancing the early or late differentiating processes of muscle stem cells. In contrast, myostatin inhibits all of the processes in the switching, proliferation, and differentiation of these cells. Better understanding of such processes in this field will contribute to repair therapies for other muscular disorders, as well as sarcopenia. 
